1
|
Giordano G, Febbraro A, Quaquarini E, Turletti A, Pedersini R, Raffaele M, Villa F, Rossello R. Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports. Oncology 2018; 94 Suppl 1:34-44. [PMID: 30041178 PMCID: PMC6193749 DOI: 10.1159/000489067] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Liver metastases are very common in metastatic breast cancer (MBC); current treatments for these lesions are based on systemic chemotherapy, endocrine- or human epidermal growth factor receptor 2 (HER2)-targeted therapy, and palliative therapy. However, no standard approach has been clearly identified for second and further chemotherapy lines in MBC patients. In the phase III clinical trial EMBRACE, eribulin was particularly effective in reducing liver lesions and improving both overall survival and progression-free survival in liver MBC patients. In this series, we collected 8 case reports of Italian clinical practice in which eribulin has shown significant efficacy in reducing liver metastases in MBC patients: complete response was reported in 2 patients, and 4 patients achieved partial response. The treatment was well tolerated, thus confirming that eribulin is a suitable therapeutic option for elderly patients and for those who have metastatic HER2-negative disease. In the setting of MBC, the sequencing of therapeutic agents should consider expected response, side effects, tumor characteristics, and patient's preferences, in order to successfully tailor the most appropriate therapy beyond earlier lines.
Collapse
Affiliation(s)
- Guido Giordano
- Medical Oncology Unit, San Filippo Neri Hospital, Rome, Italy
- Oncology Division, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
| | - Antonio Febbraro
- Medical Oncology Unit, “Sacro Cuore di Gesù Fatebenefratelli” Hospital, Benevento, Italy
| | - Erica Quaquarini
- Operative Unit of Medical Oncology, ICS Maugeri-IRCCS, Pavia, Italy
| | | | - Rebecca Pedersini
- Breast Unit-Oncology Department, Spedali Civili Hospital, Brescia, Italy
| | - Mimma Raffaele
- UOSD Oncologia Presidio Cassia, Sant'Andrea-Dipartimento Oncologico ASL, Rome, Italy
| | - Federica Villa
- S.C. Oncologia Medica, Dipartimento Oncologico Aziendale, ASST Lecco, Lecco, Italy
| | - Rosalba Rossello
- Oncologia Medica dell'Ospedale S. Vicenzo di Taormina, Taormina, Italy
| |
Collapse
|
2
|
Ro J, Cheng FTF, Sriuranpong V, Villalon A, Smruti BK, Tsang J, Yap YS. Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide. J Breast Cancer 2016; 19:8-17. [PMID: 27066091 PMCID: PMC4822111 DOI: 10.4048/jbc.2016.19.1.8] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2015] [Accepted: 02/18/2016] [Indexed: 01/07/2023] Open
Abstract
Eribulin, an antimicrotubule chemotherapeutic agent, is approved for the treatment of pretreated metastatic breast cancer (mBC) based on the positive outcomes of phase II and phase III clinical trials, which enrolled mainly Western patients. Eribulin has recently been approved in an increasing number of Asian countries; however, there is limited clinical experience in using the drug in certain countries. Therefore, we established an Asian working group to provide practical guidance for eribulin use based on our clinical experience. This paper summarizes the key clinical trials, and the management recommendations for the reported adverse events (AEs) of eribulin in mBC treatment, with an emphasis on those that are relevant to Asian patients, followed by further elaboration of our eribulin clinical experience. It is anticipated that this clinical practice guide will improve the management of AEs resulting from eribulin treatment, which will ensure that patients receive the maximum treatment benefit.
Collapse
Affiliation(s)
- Jungsil Ro
- Center for Breast Cancer, National Cancer Center, Goyang, Korea
| | | | - Virote Sriuranpong
- Division of Medical Oncology, Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
| | - Antonio Villalon
- Department of Internal Medicine, Manila Doctor Hospital, Manila, Philippines
| | - B. K Smruti
- Division of Medical Oncology, Bombay Hospital Institute of Medical Sciences & Lilavati Hospital, Mumbai, India
| | - Janice Tsang
- Department of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
| | - Yoon Sim Yap
- Department of Medical Oncology, National Cancer Centre Singapore, Singapore
| | | |
Collapse
|
3
|
Borgonovo K, Petrelli F, Cabiddu M, Ghilardi M, Coinu A, Seghezzi S, Barni S. Long response to eribulin in breast cancer: a case report. Future Oncol 2015; 11:3-8. [DOI: 10.2217/fon.15.146] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
No definitive cure is available for metastatic breast cancer and current therapies mainly focus on symptom control and minimization of adverse events to extend survival and maintain a good quality of life. Current treatment options include hormonal and chemotherapeutic agents which are characterized by different toxicity profiles and are selected based on patients’ performance status and prior therapies. Eribulin is a microtubule dynamic inhibitor which acts by sequestering tubulin molecules into aggregates, thus preventing microtubule growth and causing apoptosis. Many studies show that heavily pretreated metastatic breast cancer patients benefit from eribulin treatment both in terms of efficacy and for the favorable toxicity profile. In the Phase III EMBRACE study, eribulin treatment resulted in a significant improvement in overall survival. We report here the case of a patient who experienced a time to progression of several months with eribulin after three lines of chemotherapy and two lines of hormonal therapy.
Collapse
Affiliation(s)
- Karen Borgonovo
- Oncology Department, Azienda Ospedaliera di Treviglio, Treviglio (BG), Italy
| | - Fausto Petrelli
- Oncology Department, Azienda Ospedaliera di Treviglio, Treviglio (BG), Italy
| | - Mary Cabiddu
- Oncology Department, Azienda Ospedaliera di Treviglio, Treviglio (BG), Italy
| | - Mara Ghilardi
- Oncology Department, Azienda Ospedaliera di Treviglio, Treviglio (BG), Italy
| | - Andrea Coinu
- Oncology Department, Azienda Ospedaliera di Treviglio, Treviglio (BG), Italy
| | - Silvia Seghezzi
- Nuclear Medicine Unit, Azienda Ospedaliera di Treviglio, Treviglio (BG), Italy
| | - Sandro Barni
- Oncology Department, Azienda Ospedaliera di Treviglio, Treviglio (BG), Italy
| |
Collapse
|
4
|
Leo L, Caputo F, Sarno AD, Garofano T, Andreozzi F, Massaro MG, Montesarchio V. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report. Future Oncol 2015; 11:27-30. [DOI: 10.2217/fon.15.150] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
In this short paper, we report our experience with eribulin mesylate in a heavily pretreated breast cancer patient with multiple bone metastases. The patient had been treated with doxorubicin, cyclophosphamide, methotrexate, fluorouracil, tamoxifen, letrozole, LH-RH analogs, fulvestrant, bevacizumab and paclitaxel and liposomal doxorubicin. In November 2013 treatment with eribulin ready to use solution (1.23 mg/m2 days 1 and 8 of a 21-day cycle) was started and administered for a total of 14 courses. After six cycles of eribulin, evaluation with MRI showed a marked decrease in neoplastic involvement and replacement of osteolytic lesions with osteoblastic ones. No unexpected acute toxicity was observed. Although with all the limitations of any anecdotal report, our experience documents the efficacy and safety of eribulin in this difficult-to-treat patient who had been treated with multiple lines of chemotherapy.
Collapse
Affiliation(s)
- Luigi Leo
- Oncology Unit, Azienda Ospedaliera dei Colli, Naples, Italy
| | | | | | | | | | | | | |
Collapse
|
5
|
Oostendorp LJM, Stalmeier PFM, Donders ART, van der Graaf WTA, Ottevanger PB. Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncol 2011; 12:1053-61. [PMID: 21621462 DOI: 10.1016/s1470-2045(11)70045-6] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
No standard monotherapy or combination palliative chemotherapy currently exists for patients with advanced breast cancer pretreated with anthracyclines and taxanes. In this systematic review we assess the current knowledge on the efficacy and safety of palliative single-agent chemotherapy drugs--capecitabine, vinorelbine, gemcitabine, and liposomal doxorubicin--commonly used in daily clinical practice. We identified 22 studies, of which ten investigated capecitabine, nine investigated vinorelbine, three investigated gemcitabine, and one investigated liposomal doxorubicin. The greatest amount of information was available for capecitabine and vinorelbine. These two drugs showed good efficacy. The disease control rate differed significantly between the four drugs, which is relevant in terms of how well tumour symptoms can be improved and whether quality of life can be maintained or even improved. To obtain more evidence of the efficacy and safety of chemotherapeutic agents used in this pretreated population of advanced breast cancer patients, randomised comparisons of the various drugs, as monotherapy and in combination with targeted agents, are needed.
Collapse
Affiliation(s)
- Linda J M Oostendorp
- Department of Epidemiology, Biostatistics, HTA, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
| | | | | | | | | |
Collapse
|
6
|
Scorsolini-Comin F, Santos MAD, Souza LVE. Vivências e discursos de mulheres mastectomizadas: negociações e desafios do câncer de mama. ESTUDOS DE PSICOLOGIA (NATAL) 2009. [DOI: 10.1590/s1413-294x2009000100006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
O presente artigo investiga as experiências de mulheres mastectomizadas tais como estas se presentificam em seus discursos sobre a vivência do câncer de mama, bem como suas estratégias de negociação dos desafios da doença. Foram analisadas 11 sessões de um grupo de apoio ocorridas em um serviço de atendimento público. A partir da análise temática das sessões, com o auxílio dos princípios do dialogismo e da polifonia, a partir do referencial histórico-cultural, pôde ser percebida a oposição entre o saber científico ("sentença" médica) e o saber popular (possibilidade de cura), bem como a questão do estigma social associado ao câncer e ao gênero feminino. O grupo constituiu-se como um espaço para que esses diferentes saberes se atualizassem e fossem transmitidos, refletindo uma construção coletiva das ideias em torno do câncer, o que permitiu ressignificar os modos de enfrentamento e as diversas vivências relacionadas à doença.
Collapse
|
7
|
Campbell JD, Ramsey SD. The costs of treating breast cancer in the US: a synthesis of published evidence. PHARMACOECONOMICS 2009; 27:199-209. [PMID: 19354340 DOI: 10.2165/00019053-200927030-00003] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Published estimates for the treatment costs of breast cancer vary widely in methodology, perspective, patient populations and time horizon. We systematically summarized and analysed the published literature on per-patient costs of breast cancer, and highlight the perspectives, populations studied, time horizons and future directions for cost studies in breast cancer. This review included 29 US cost-of-illness studies for breast cancer. The estimates of lifetime per-patient costs of breast cancer ranged from $US20 000 to $US100 000. Payer perspectives were popular, while disease stages I and II were emphasized. The costs of initial and terminal therapy were greater than continuing care on a per-unit time basis, but continuing care accounts for the largest share of lifetime cost due to the relatively long survival of breast cancer patients. Costs of different surgeries were relatively similar (breast-conserving surgery vs mastectomy) but, all else equal, significant costs ($US23 000-31 000) were observed for patients who received adjuvant chemotherapy compared with those who did not. Multiple studies confirmed that costs increased with increased stage of disease and costs decreased with increased age of diagnosis. The question remains whether or not lower costs for elderly patients are associated with lower quality of care. The patient, employer and societal perspectives were rarely presented. Experts in the field have recommended the societal perspective for US-based cost-effectiveness analyses. Most lifetime cost estimates were likely an underestimate for today's lifetime cost of treating breast cancer because of changes in practice patterns and improved survival. Further societal-based cost studies that differentiate costs by stage, age and treatment time (initial, continuing and terminal), and include the latest practice patterns would be valuable toward informing US-based cost-effectiveness studies for preventive as well as breast cancer treatment interventions.
Collapse
|